Clinical Trial Update: Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) [Phase 1, Phase 2]

View source ↗

Summary

A combined alternating regimen of sunitinib and bevacizumab is being investigated in Phase 1/2 for advanced renal cell carcinoma in a clinical trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Sunitinib (sunitinib)

Snippet

Sponsor: King Faisal Specialist Hospital & Research Center | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN